Caption Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Caption Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,000	Closed	-$11.1M	–	2073
2025 Q2	$11.1M	Sell	25,000 -5,000	-17%	-$2.3M	0.12%	182
2025 Q1	$14.5M	Buy	+30,000	New	+$14M	0.14%	129
2024 Q4	–	Sell	-50,000	Closed	-$23.3M	–	1861
2024 Q3	$23.3M	Buy	+50,000	New	+$24M	0.37%	57
2024 Q1	–	Sell	-6,000	Closed	-$2.44M	–	1698
2023 Q4	$2.44M	Sell	6,000 -23,000	-79%	-$8.5M	0.03%	560
2023 Q3	$10.1M	Buy	+29,000	New	+$10.1M	0.16%	156
2022 Q1	–	Sell	-50,000	Closed	-$11M	–	1983
2021 Q4	$11M	Sell	50,000 -15,000	-23%	-$2.92M	0.12%	204
2021 Q3	$11.8M	Buy	+65,000	New	+$12.7M	0.13%	196
2020 Q4	–	Sell	-8,000	Closed	-$2.18M	–	1270
2020 Q3	$2.18M	Buy	+8,000	New	+$2.21M	0.05%	407
2019 Q3	–	Sell	-25,000	Closed	-$4.58M	–	917
2019 Q2	$4.58M	Sell	25,000 -10,000	-29%	-$1.75M	0.23%	124
2019 Q1	$6.44M	Buy	+35,000	New	+$6.46M	0.35%	78

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Caption Management's VRTX Position: Q1 2026 in Review

Caption Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 200 shares worth $89.3K. The stake represents ﹤0.01% of the portfolio and ranks #1401 among its holdings. This is a return to the name: Caption Management previously reported a position in VRTX as recently as Q1 2024.

Caption Management first reported a position in VRTX in Q3 2021 and has held it in 5 quarters since. The position peaked at $12.6M in Q1 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Caption Management held 200 shares of Vertex Pharmaceuticals worth $89.3K as of Q1 2026.
Vertex Pharmaceuticals was a new Caption Management position in Q1 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1401 holding.
Caption Management first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 5 quarters since.
Caption Management's Vertex Pharmaceuticals position peaked at $12.6M in Q1 2022.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.